Moderna and the european commission agree on amendment to covid-19 vaccine supply agreement

Cambridge, ma / accesswire / june 2, 2022 / moderna, inc.(nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced an agreement with the european commission (ec) to amend their originally agreed contractual delivery schedules for the moderna covid-19 vaccine booster product (spikevax, mrna-1273) or updated booster vaccine candidate. the amendment allows participating member states to have moderna covid-19 vaccine booster doses scheduled for delivery in the second quarter of 2022 to be delivered later in calendar year 2022 or early calendar year 2023.
MRNA Ratings Summary
MRNA Quant Ranking